Jiménez-Alcaide, 1,349 patient various antiandrogen prophylaxis study: 33% lower mortality [p=0.41], 8% higher progression [p=0.77], and 68% more cases [p=0.15] https://c19p.org/jimenezalcaide
copied to clipboard
Influence of androgen deprivation therapy on the severity of COVID‐19 in prostate cancer patients
et al., The Prostate, doi:10.1002/pros.24232
Retrospective 1,349 prostate cancer patients in Spain, 156 on ADT, showing no significant differences in COVID-19 outcomes with treatment.
|
risk of death, 33.0% lower, RR 0.67, p = 0.41, treatment 3 of 11 (27.3%), control 17 of 50 (34.0%), adjusted per study, multivariable.
|
|
risk of progression, 8.0% higher, RR 1.08, p = 0.77, treatment 11, control 50, adjusted per study, multivariable.
|
|
risk of case, 68.2% higher, RR 1.68, p = 0.15, treatment 11 of 156 (7.1%), control 50 of 1,193 (4.2%), excluded in exclusion analyses:
excessive unadjusted differences between groups.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Jiménez-Alcaide et al., 9/13/2021, retrospective, Spain, Europe, peer-reviewed, 9 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.